Juan Pasquau
About
Juan Pasquau is a scholar working on Infectious Diseases, Virology and Epidemiology.
According to data from OpenAlex, Juan Pasquau has authored 60 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Infectious Diseases, 27 papers in Virology and 19 papers in Epidemiology. Recurrent topics in Juan Pasquau's work include HIV/AIDS drug development and treatment (34 papers), HIV Research and Treatment (27 papers) and HIV/AIDS Research and Interventions (27 papers). Juan Pasquau is often cited by papers focused on HIV/AIDS drug development and treatment (34 papers), HIV Research and Treatment (27 papers) and HIV/AIDS Research and Interventions (27 papers). Juan Pasquau collaborates with scholars based in Spain, United Kingdom and Palestinian Territory. Juan Pasquau's co-authors include Rafael Rubio, Federico Pulido, Carmen Hidalgo-Tenorio, Rafaël Delgado, Joaquín Portilla, Alberto Arranz, José Ramón Arribas, Maria Jesús Pérez‐Elías, Antonio Rivero and José Antonio Iribarren and has published in prestigious journals such as PLoS ONE, Journal of Clinical Microbiology and The Lancet Infectious Diseases.
In The Last Decade
Juan Pasquau
59 papers receiving 1.1k citations
Peers
Juan Pasquau
Alexia Cusini Switzerland
Lauren Komarow United States
Lucia Taramasso Italy
Veronica Ravasio Italy
Marc Foca United States
Nadia Valin France
Kerrie Watson Australia
Éric Cua France
E.G.L. Wilkins United Kingdom
Michel Duong France
Citations per year, relative to Juan Pasquau Juan Pasquau (= 1×)
peers
Alexia Cusini
Countries citing papers authored by Juan Pasquau
Since
Specialization
Citations
This map shows the geographic impact of Juan Pasquau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juan Pasquau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juan Pasquau more than expected).
Fields of papers citing papers by Juan Pasquau
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Juan Pasquau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juan Pasquau. The network helps show where Juan Pasquau may publish in the future.
Co-authorship network of co-authors of Juan Pasquau
This figure shows the co-authorship network connecting the top 25 collaborators of Juan Pasquau. A scholar is included among the top collaborators of Juan Pasquau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juan Pasquau. Juan Pasquau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hidalgo‐Tenorio, Carmen, Patricia Muñóz, Antonio Plata, et al.. (2023). EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci. International Journal of Antimicrobial Agents. 62(3). 106918–106918.
2.
Hidalgo‐Tenorio, Carmen, et al.. (2021). Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years. Viruses. 13(2). 144–144.
3.
Hidalgo‐Tenorio, Carmen, et al.. (2021). Risk factors for ≥high-grade anal intraepithelial lesions in MSM living with HIV and the response to topical and surgical treatments. PLoS ONE. 16(2). e0245870–e0245870.
4.
Hidalgo‐Tenorio, Carmen, et al.. (2019). ART is key to clearing oncogenic HPV genotypes (HR-HPV) in anal mucosa of HIV-positive MSM. PLoS ONE. 14(10). e0224183–e0224183.
5.
López‐Ruz, Miguel Ángel, M. Carmen Gonzálvo, Antonio Sampedro, et al.. (2018). Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients. PLoS ONE. 13(4). e0196257–e0196257.
6.
Pasquau, Juan, Carmen Hidalgo-Tenorio, Marisa Montes, et al.. (2018). High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial. PLoS ONE. 13(4). e0195068–e0195068.
7.
Gutiérrez‐Valencia, Alicia, Coral García, Pompeyo Viciana, et al.. (2018). No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients. PLoS ONE. 13(9). e0203452–e0203452.
8.
Chueca, Natalia, Marta Álvarez, Juan Pasquau, et al.. (2017). High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach. PLoS ONE. 12(10). e0186928–e0186928.
9.
Hidalgo-Tenorio, Carmen, et al.. (2017). Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM). AIDS Research and Therapy. 14(1). 34–34.
10.
Hidalgo-Tenorio, Carmen, et al.. (2017). Alta prevalencia e incidencia de lesiones precursoras de cáncer anal asociada a la infección por VPH en mujeres VIH positivas en la era tardía del TAR. Enfermedades Infecciosas y Microbiología Clínica. 36(9). 555–562.
11.
Chueca, Natalia, Marta Álvarez, Juan Pasquau, et al.. (2016). Phylodynamic and Phylogeographic Profiles of Subtype B HIV-1 Epidemics in South Spain. PLoS ONE. 11(12). e0168099–e0168099.
12.
Poveda, Eva, José Hernández‐Quero, Maria Jesús Pérez‐Elías, et al.. (2016). Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48‐week analysis of results from the PROTEST study. HIV Medicine. 18(7). 482–489.
13.
Blanco, José Ramón, David Arroyo-Manzano, Manuel Crespo, et al.. (2015). The Efficacy and Safety of Maraviroc Addition to a Stable Antiretroviral Regimen in Subjects with Suppressed Plasma HIV-RNA Is Not Influenced by Age. AIDS Research and Human Retroviruses. 31(9). 893–897.
14.
Pérez‐Molina, José A., Rafael Rubio, Antonio Rivero, et al.. (2015). Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. The Lancet Infectious Diseases. 15(7). 775–784.
15.
Chueca, Natalia, Juan Pasquau, Mohamed Omar, et al.. (2015). Los estudios de resistencias a antirretrovirales como herramienta para el análisis de los clusters de transmisión del virus de la inmunodeficiencia humana. Enfermedades Infecciosas y Microbiología Clínica. 33(9). 603–608.
16.
García, Féderico, Eva Poveda, Maria Jesús Pérez‐Elías, et al.. (2014). Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48‐week analysis of the PROTEST study. Journal of the International AIDS Society. 17(4S3). 19520–19520.
17.
Merchante, Nicolás, Luís F. López‐Cortés, Maria José Ríos-Villegas, et al.. (2011). Liver Toxicity of Antiretroviral Combinations Including Fosamprenavir Plus Ritonavir 1400/100 mg Once Daily in HIV/Hepatitis C Virus-Coinfected Patients. AIDS Patient Care and STDs. 25(7). 395–402.
18.
López‐Cortés, Luís F., Pompeyo Viciana, Rosa Ruiz-Valderas, et al.. (2010). Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study. AIDS Research and Therapy. 7(1). 5–5.
19.
Macı́as, Juan, A. Rivero, Pompeyo Viciana, et al.. (2008). Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis. Journal of Antimicrobial Chemotherapy. 63(1). 178–183.
20.
Laguna, Fernando Ballester, Rogelio López‐Vélez, Federico Pulido, et al.. (1999). Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS. 13(9). 1063–1069.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alexia Cusini Breakdown of academic impact, for papers by Lauren Komarow Breakdown of academic impact, for papers by Lucia Taramasso Breakdown of academic impact, for papers by Veronica Ravasio Breakdown of academic impact, for papers by Marc Foca Breakdown of academic impact, for papers by Nadia Valin Breakdown of academic impact, for papers by Kerrie Watson Breakdown of academic impact, for papers by Éric Cua Breakdown of academic impact, for papers by E.G.L. Wilkins Breakdown of academic impact, for papers by Michel Duong